Replies to post #611 on Idenix Pharmaceuticals (IDIX)

[gofishmarko]

Thanks for the updates on sales figures.

Using the 1/26 and 2/23 figures , you can say that both new and total RXs are growing at > 50% per month.

At that rate of growth , Tyzeka will have the entire nuke market to itself in a year or so.

;-))

[go seek]

Tyzeka Sales... update
3/23: 55 NRx, 90 TRx; 2.7% new, 1.3% total
2/23: 59 NRx, 92 TRx; 3.1% new, 1.4% total
2/9: 55 NRx, 83 TRx; 2.6% new, 1.2% total
1/26: 41 NRx, 60 TRx; 2.0% new, 0.9% total

The "new" figure refers to Tyzeka’s market share in the given week among new prescriptions for all HBV drugs.

The "total" figure refers to Tyzeka’s market share in the given week among total prescriptions—new and refills—for all HBV drugs.

For a recently-launched drug such as Tyzeka, the market share of new prescriptions is a more useful gauge than the market share of total prescriptions.

SOURCE: rkrw on SI IDIX Board